A Friday footnote: The New England Journal of Medicine has published the Moderna influenza vaccine data -- the same that led the FDA's CBER division to refuse to review the vaccine under Vinay Prasad. (That decision, called a refuse-to-file or RTF, was later reversed.)
The data had been presented to investors but this was peer-reviewed and there are some wrinkles worth looking at. First, the efficacy slide.